SCHEMBL4050873

SCHEMBL4050873

COc1cccc(-c2nc3ncc(-c4cccc(C(F)(F)F)c4)cc3[nH]2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.58
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP3A4 P08684 1/20 0.46
THRB P10828 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
STAT6 P42226 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HIF1A Q16665 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059872 0.91 AURKA (0.61) AURKAGRIN1GRIN2BIKBKETBK1
SCHEMBL4062482 0.90 AURKA (0.70) AURKACYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL4051797 0.89 AURKA (0.44) AURKACYP1A2CYP2C9MEN1KMT2A
SCHEMBL4058139 0.86 AURKA (0.62) AURKACYP1A2CYP2C9HTTSMN1; SMN2
SCHEMBL4055330 0.85 AURKA (0.67) AURKACYP1A2CYP2C9KDM4ENPC1
SCHEMBL4057030 0.85 SCN2A (0.53) AURKACYP1A2CYP2C9MEN1KMT2A
SCHEMBL4058461 0.85 SCN2A (0.56) AURKACYP1A2CYP2C9MEN1KMT2A
SCHEMBL4059434 0.85 AURKA (0.63) AURKACYP1A2CYP2C9KDM4ENPC1
SCHEMBL4052372 0.84 AURKA (0.69) AURKAKDM4ENPC1ALDH1A1HPGD
SCHEMBL4061866 0.84 AURKA (0.57) AURKAKDM4ENPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885CYP1A2 617/4885CYP2C9 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.